Health ❯ Oncology

Clinical Trials

Drug Development Combination Therapies Patient Care Pancreatic Cancer Chemotherapy Genetic Research Phase III Trials Combination Therapy FDA Regulations Drug Development Phases Lung Cancer Immunotherapy

4 ARTICLES

last mo.

Moderna and Merck Report Positive Phase 3 Topline for Personalized Melanoma Vaccine

A topline interim readout pushed Moderna shares to multiyear highs and preceded a $2.6 billion financing ahead of detailed results at the Oct. 24 ESMO presentation.

7 ARTICLES

2mo ago

AstraZeneca Stops Phase III Volrustomig Lung Cancer Trial

7 ARTICLES

4mo ago

EMA Opens Rolling Review as U.S. Hospitals Start Early Access to Daraxonrasib

6 ARTICLES

9mo ago

Moderna, Merck Melanoma Vaccine Shows Durable Five-Year Benefit as Stock Hits 52-Week High

5 ARTICLES

11mo ago

Clinical Trials

Moderna and Merck Report Positive Phase 3 Topline for Personalized Melanoma Vaccine

AstraZeneca Stops Phase III Volrustomig Lung Cancer Trial

EMA Opens Rolling Review as U.S. Hospitals Start Early Access to Daraxonrasib

Moderna, Merck Melanoma Vaccine Shows Durable Five-Year Benefit as Stock Hits 52-Week High

ECOG-ACRIN Review Finds Black AML Patients Have Worse Survival Independent of Cytogenetics